

DAFTAR PUSTAKA

- A. Pantosti dan M Vendetti. 2009. What is MRSA? *Eur Respir J* 2009; 34: 1190–1196 DOI: 10.1183/09031936.00007709.
- A.Rashid, K Rasheed, M. Akhta. Factors Influencing Vaccine Efficacy. *The Journal of Animal & Plant Sciences* 19(1): 2009, Pages: 22-25 ISSN: 1018-7081
- Abu-Hijleh MF, Habbal OA, Moqattash ST. 1995. The role of the diaphragm in lymphatic absorption from the peritoneal cavity. *J Anat* 186:453–467
- Alvrado-Sanchez, B., Hernandez-Castro, B., Portalez-Perez, D., *et al.* 2006. Regulatory T cells in patients with systemic lupus erythematosus. *Journal of Autoimmunity*, xx: 1-9.
- American College of Rheumatology Ad Hoc Committee on systemic lupus erythematosus guidelines. *Arthritis Rheum* 1999;42(9):1785-96.
- Arntsen, K.A. (2011). Lupus Facts and Knowledge. Lupus Research Institute. Diunduh dari <http://www.lupusresearchinstitute.org>.
- Barreto, M., Ferreira, R.C., Lourenco, L., *et al.* 2009. Low frequency of CD4+ CD25+ Treg in SLE patients: a heritable trait associated with *CTLA4* and *TGFβ* gene variants. *BMC Immunology*, 10(5): 1-14.
- Bermas BL, Petri M, Goldman D, *et al.* T helper cell dysfunction in systemic lupus erythematosus (SLE): Relation to disease activity. *J Clin Immunol.* 1994; 14: 169–177.
- Berube BJ, Bubeck Wardenburg. *Staphylococcus aureus* alpha-toxin: nearly a century of intrigue. *Toxins (Basel)*. 2013;5:1140–1166.
- Bogaert D, Groot Rd, Hermans PWM. Streptococcus pneumoniae colonisation: the key of pneumococcal disease. *The lancet infectious disease*. 2004;4:144-155
- Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., Montori, V. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA* 295, 2275–2285.
- Cervera R, Khamashta MA, Font J, *et al.* Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. *Medicine (Baltimore)* 2003; 82: 299–308.
- Cervera, R. Bertsias, G., Boumpas, Dimitriou. 2012. EULAR Textbook on Rheumatic Diseases.

Dhar JP, Sokol RJ. Lupus and pregnancy: Complex yet manageable. *Clin Med Res.* 2006;4:310–21.

Dixon, W. G., Watson, K., Lunt, M., Hyrich, K. L., Silman, A. J., Symmons, D. P. (2006) British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum.* 54, 2368–2376.

Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T, Cai M, Hansel NN, Perl T, Ticehurst JR, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant *Staphylococcus aureus* carrying the Panton-Valentine leukocidin genes. *Clin Infect Dis.* 2005;40:100–107.

Goldblatt F, Chambers S, Rahman A, Isenberg DA. *Serious infections in British patients with systemic lupus erythematosus: Hospitalisations and mortality in lupus.* 2009; 18: 682–689.

Guiducci, C. et al. *Nature*; published online June 17, 2010; doi:10.1038/nature09102.

Haga HJ, D'Cruz D, Asherson R, Hughes GR. Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. *Ann Rheum Dis.* 1992; 51: 885–888.

Harrington, L.E., Hatton, R.D., Mangan, P.R. Turner, H., Murphy, T.L., Murphy, K.M., Weacer, C.T. 2005. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineage. *Nature Immunology*, 6(11): 1123-1132.

Hasanah, Dian. 2012. Hubungan Kadar Vitamin D dengan Keseimbangan TGF- β /IL-6 dan Keseimbangan Treg/Th17 pada Pasien Lupus Eritematosus Sistemik. *Tesis Program Magister Ilmu Biomedik.* Fakultas Kedokteran Universitas Brawijaya.

Helmi, Luthfi. 2008. Manifestasi Systematic Lupus Erythematosus pada Paru. *Majalah Kedokteran Nusantara* Volume 41 No. 1.

Hope R, Livermore DM, Brick G, et al. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001–06. *J Antimicrob Chemother.* 2008; 62: Suppl. 2, ii65–ii74.

Itzhak, Brook. 2011. Microbiology of Sinusitis. Washington DC. *Proc Am Thorac Soc* Vol 8. pp 90–100, 2011 DOI: 10.1513/pats.201006-038RN

Jameson, Larry, et al., 2006. Harrison's Manual of Medicine. United States of America : The McGraw-Hill Companies, Inc.

- Jawetz, Melnick, and Adelberg' s. 2005. Medical Microbiology, Mc Graw-Hill Companies Inc, page 327-329.
- Kalim, H. 1996. Gambaran klinik dan harapan hidup penderita lupus eritematosus sistemik (SLE). *Majalah Kedokteran Indonesia*, 46: 383-384
- Kimura, A. dan Kishimoto, T. 2010. IL-6: Regulator of Treg/Th17 balance. *European Journal of Immunology*, 40: 1830-1835.
- Kineret 100 mg solution for injection [summary of product characteristics]. Stockholm, Sweden: Biovitrum AB, 2009.
- Kwambana BA, Barer MR, Bottomley C, Adegbola RA, Antonio M. Early acquisition and high nasopharyngeal co-colonisation by *Streptococcus pneumoniae* and three respiratory pathogens amongst Gambian newborns and infants. *BMC Infect Dis*. 2011 Jun 20;11:175. doi: 10.1186/1471-2334-11-175. PMID:21689403
- L.Delavelle, E. Duvallet, L. Semerano, *et al.* Anti cytokine vaccination in autoimmune diseases. *Swiss Med Wkly*. 2010;140:w13108.
- L. Semerano, E. Assier, L. Dellevalle, *et al.*, Kinoid of human tumor necrosis factor alpha for rheumatoid arthritis. *Expert Opin Biol Ther*. 2011;11:545-550.
- Lyon B, Skurray R. Antimicrobial resistance of Staphylococcus aureus: genetic basis. *Microbiol Rev* 1987; 51: 88–134.
- Maruli, A. (2011). Lupus dan Harapan yang Tak Pernah Pupus. Antara. Diunduh dari <http://www.antaraneews.com>.
- Nalbandian, A., Crispin, J.C., Tsokos, G.C. 2009. Interleukin-17 and systemic lupus erythematosus: current concepts. *Clinical and Experimental Immunology*,157: 209-215.
- Pathtak, S. dan Mohan, C. 2011. Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models. *Arthritis Research and Therapy*, 13(241): 1-9.
- Pantosti A, Sanchini A, Monaco M. 2007. Mechanisms of antibiotic resistance in Staphylococcus aureus. *Future Microbiol* 2007; 2: 323–334.
- Perhimpunan Reumatologi Indonesia. 2011. Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik.
- Petri M. Infection in systemic lupus erythematosus. *Rheum Dis Clin North Am* 1998; 24: 423–456.
- Rahman, Anisur, Isenberg, David. 2008. Mechanism of Systemic Lupus Eritematosus. *N. Engl J Med* 358;9.

Ramsey, I. and T. Bryn. 2001. Manual of canine and feline infectious diseases. BSAVA, 46-48.

Ranuh, I.G.N. 2008. *Pedoman Imunisasi di Indonesia*. Edisi ketiga. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia.

Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. *Rheumatology (Oxford)* 2012; 51: 1145–1153.

Rohn, T.A., Jennings, G.T., Hernandez, M., Grest, P., Beck, M., Zou, Y., Kopf, M., Bachmann, M.F. 2006. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. *Eur J Immunol*, 36:2857-2867.

Rottman, J.B. dan Willis, C.R. 2010. Mouse models of systemic lupus erythematosus reveal a complex pathogenesis. *Veterinary Pathology*, 47(4): 4664-4676.

Rubbert, Andrea. 2012. Assessing the safety of biologic agents in patients with rheumatoid arthritis. *Rheumatology* 2012;51:v38_v47 doi:10.1093/rheumatology/kes114.

Sherer Y, Shoenfeld Y. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. *Autoimmun Rev* 2006;153–155.155.

Syahrurachman, *et al.*, 2010. *Buku Ajar Mikrobiologi Kedokteran*. Edisi Revisi. Jakarta: Binarupa Aksara, 24-32.

Turner, Patricia, Brabb, Thea, *et al.*, 2011. Administration of Substances to Laboratory Animals: Routes of Administration and Factors to Consider. *J Am Assoc Lab Anim Sci*. 2011 Sep; 50(5): 600–613.

Tony HP, Burmester G, Schulze-Koops H, *et al.* Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national registry (GRAID). *Arthritis Res Ther*. 2011; 13: R75.

Toruner, Cagri, Diamond, Betty. 2011. Current and novel therapeutic in the treatment of systemic lupus erythematosus. 2011. *J. Allergy Clin Immunology Volume 127 Number 2*.

Vincent FB, Morand EF, Mackay F: BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. *Immunol Cell Biol*. 2012, 90: 293-303. 10.1038/icb.2011.111.

Yang, J., Chu, Y., Yang, X., *et al.* 2009. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. *Arthritis and Rheumatism*. 60: 1472- 1483.

- Yat, Desmond. 2010. Cytokines and Their Roles in the Pathogenesis of Systemic Lupus Erythematosus: From Basics to Recent Advances. Hindawi Publishing Corporation Journal of Biomedicine and Biotechnology. Volume 2010, Article ID 365083.
- Wang, J., Ioan-Facsinay, A., van der Voort, E.H., Huizinga, T.W.J., Toes, R.E.M. 2007. Transient expression of FoxP3 in human activated nonregulatory CD4+ T cells. *European Journal of Immunology*, 37: 129-138.
- Wong, C.K., Lit, L.C., Tam, L.S., Li, E.K., Wong, P.T., Lam, C.W. 2008. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in autoimmunity. *Clinical Immunology*, 127: 385-393.
- Zagury, D., Le Buanec, H., Mathian, A., *et al.* 2009. IFN α kinoid vaccine-induced neutralizing antibodies prevent clinical manifestation in a lupus flare murine model. *PNAS*, 106(13):5294-5299.

